By Business/Source
Currency:SGD
2024/FY
Stock NameRevenueRatio
Oncology services73.57M94.10%
Cellular and gene therapy related products and services4.61M5.90%
By Country/Region
Currency:SGD
2024/FY
Stock NameRevenueRatio
Singapore71.51M91.46%
China and Hong Kong2.87M3.67%
United States of America2.12M2.71%
Australia1.66M2.12%
Vietnam30K0.04%
